Treatment of moderate-severe psoriasis in Colombia: a survey conducted with colombian dermatologists
DOI:
https://doi.org/10.29176/2590843X.1923Keywords:
psoriasis, therapeutics, dermatology, psoriatic arthritisAbstract
Introduction: in Colombia, until now, there is no information on dermatologists’ pharmacological preferences in the treatment for psoriasis.
Materials and methods: descriptive cross-sectional study using a survey, completed by dermatologists from the Colombian Association of Dermatology and Dermatological Surgery (AsoColDerma). The data analysis was with frequencies and percentages for qualitative variables and measures of central tendency for quantitative variables.
Results: fifty-six dermatologists were included. 58.8% consider phototherapy or topical therapies as the first line of treatment. 58.9% consider transition to biological therapy with the failure of conventional systemic therapy. 53.6% prefer interleukin (IL) 17 inhibitors as the first line of biological therapy.
Conclusions: dermatologists in Colombia follow the global trend of giving classic systemic therapy as the first or second line of treatment before starting biological therapy (1–3), and the favorite first-line biological agents are the anti-IL-17 agents available in the country. This is the first study in Colombia that characterizes the treatment of psoriasis and allows us to know treatment trends, which opens the way for follow-up studies that evaluate changes in therapeutic behaviors according to the creation of new knowledge and updating of the information in the country.
Author Biographies
Lina M. Isaza-Valencia, Pontificia Universidad Javeriana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario San Ignacio. Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.
Alejandro Castellanos-Angarita, Pontificia Universidad Javeriana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario San Ignacio. Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.
Nestor Correa-Gonzalez, Hospital Universitario San Ignacio, Bogotá, Colombia
Facultad de Medicina, Pontificia Universidad Javeriana. Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia.
Juliana Ordoñez-Parra, Pontificia Universidad Javeriana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario San Ignacio. Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.
Carolina Cortes-Correa, Hospital Universitario de la Samaritana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario de la Samaritana, Bogotá, Colombia.
Elkin Peñaranda, Hospital Universitario de la Samaritana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario de la Samaritana, Bogotá, Colombia.
Margarita Tamayo-Buendia, Pontificia Universidad Javeriana, Bogotá, Colombia
Unidad de Dermatología, Hospital Universitario San Ignacio. Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia.
References
López-Estebaranz JL, de la Cueva-Dobao P, de la Torre Fraga C, Galán Gutiérrez M, González Guerra E, Mollet Sánchez J, et al. Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals. Actas Dermosifiliogr. 2018;109(7):631–42.
Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. Clin Drug Investig. 2017;37(5):493–501.
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–5.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
Masson W, Lobo M, Molinero G. Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther. 2020;37(5):2017–33.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.
Fernández-Ávila DG, Charry Anzola LP, González-Cardona LP. Prevalencia de psoriasis en Colombia según datos del Registro Nacional en Salud. Actas Dermosifiliogr. 2022;113(3):339–41.
González C, Castro LA, Cruz GD la, Arenas CM, Beltrán A, Santos AM. Caracterización epidemiológica de la psoriasis en el Hospital Militar Central. Rev Asoc Colomb Dermatol Cir Dermatol. 2009;17(1):11–7.
Coates LC, Corp N, van der Windt DA, O’Sullivan D, Soriano ER, Kavanaugh A. GRAPPA Treatment Recommendations: 2021 Update. J Rheumatol. 2022;49(6):52–4.
Castro JR, Manuel A, Franco D, César F, González F, Ángela A, et al. Guía de práctica clínica para el tratamiento de la psoriasis en Colombia: ACTUALIZACIÓN 2022. Rev Asoc Colomb Dermatol Cir Dermatol. 2022.
Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369–75.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2).
Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2(SUPPL. 2):10–6.
Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155(4):707–13.
Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–9.
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–9.
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–86.
Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, et al. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2021;32(2):203–11.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
Bagel J, Glick B, Wu JJ, Chopra I, Song X, Brouillette M, et al. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. J Med Econ. 2021;24(1):782–91.
Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95–105.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;2022(5).
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Lina M. Isaza-Valencia, Alejandro Castellanos-Angarita, Nestor Correa-Gonzalez, Juliana Ordoñez-Parra, Carolina Cortes-Correa, Elkin Peñaranda, Margarita Tamayo-Buendia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
